Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Ondine Biomedical, Inc. ( (GB:OBI) ) has shared an update.
Ondine Biomedical Inc. is set to commence a Phase 3 clinical trial in the US for its nasal photodisinfection technology, Steriwave®. The trial, conducted in collaboration with HCA Healthcare, aims to assess the efficacy of this technology in preventing infections during major surgeries. This initiative is pivotal for Ondine as it seeks FDA approval, marking a significant milestone in its operational and strategic trajectory. The trial will involve approximately 5,000 patients across 14 hospital sites, with early results expected in Autumn 2025.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, also known as photodisinfection. The company has a range of investigational products based on its proprietary photodisinfection technology, which are in various stages of development. Their nasal photodisinfection system, branded as Steriwave® outside the US, is already approved in several countries and is undergoing clinical trials for regulatory approval in the US.
YTD Price Performance: -13.14%
Average Trading Volume: 447,536
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £30.7M
See more data about OBI stock on TipRanks’ Stock Analysis page.
